Revenue fell 10.5% YoY as operating loss narrowed 88% on lower impairment charges

Filed July 31, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read

Key Changes

• high

  Total revenue declined 10.5% YoY to $190.7M (Q2 FY26 vs Q2 FY25), while operating loss narrowed 88% from -$329.2M to -$38.9M as the prior-year quarter carried $234.7M goodwill and $82M intangible impairments.

  Notes: Revenue & Operating Results view on EDGAR →
• high

  Replaced $115M ABL facility with $200M OrbiMed term loan (10.1–10.4% interest, maturity July 2030); new facility includes monthly revenue covenant starting at $615M (Dec 2025) and stepping to $974M by Dec 2029.

  Notes: Long-Term Debt verify on EDGAR →
• high

  Recognized $4.5M goodwill impairment in Q1 FY26, writing Women's Health reporting unit goodwill to zero following prior-year $143.5M charge to the same unit.

  Notes: Goodwill Impairment verify on EDGAR →